RayzeBio (RYZB) has updated terms for a proposed $224M initial public offering.
The radiopharmaceuticals developer said in an SEC filing that it was interested in offering 13.2M shares priced between $16 and $18, which would raise around $224M if priced at the midpoint. Underwriters would be granted a 30-day option to buy up to 2.2M additional shares to cover over-allotments.
An existing shareholder also plans to offer an additional 1.2M shares. RayzeBio wouldn’t see any proceeds from that sale.
RayzeBio hopes to list its shares on Nasdaq under the symbol RYZB. JP Morgan, Jefferies, Evercore ISI and Truist Securities are serving as joint bookrunners.
The company first filed for the IPO in August.